BR112018003171A2 - composto de tetrahidrooxepinopiridina - Google Patents

composto de tetrahidrooxepinopiridina

Info

Publication number
BR112018003171A2
BR112018003171A2 BR112018003171-2A BR112018003171A BR112018003171A2 BR 112018003171 A2 BR112018003171 A2 BR 112018003171A2 BR 112018003171 A BR112018003171 A BR 112018003171A BR 112018003171 A2 BR112018003171 A2 BR 112018003171A2
Authority
BR
Brazil
Prior art keywords
receptor
nach
activity
compound
kisepino
Prior art date
Application number
BR112018003171-2A
Other languages
English (en)
Japanese (ja)
Other versions
BR112018003171B1 (pt
Inventor
Koganemaru Yohei
Miyamoto Satoshi
Nagashima Shinya
Kamikawa Akio
Yonezawa Koichi
Koizumi Yuka
Aoki Satoshi
Ogiyama Takashi
Kawakami Shimpei
Kunikawa Shigeki
Sato Ryo
Shishikura Junichi
Kakimoto Shuichirou
Yamada Hiroshi
Tamaki Keisuke
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of BR112018003171A2 publication Critical patent/BR112018003171A2/pt
Publication of BR112018003171B1 publication Critical patent/BR112018003171B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

problema: é proposto um composto com atividade de modulador alostérico positivo (atividade de map) sobre um receptor nicotínico de acetilcolina a7 (receptor nach a7). meios para solução: os presentes inventores estudaram a atividade de map sobre um receptor nach a7 e descobriram que um composto de tetrahidrooxepinopi-ridina possui atividade de map sobre um receptor nach a7, obtendo assim a pre-sente invenção. o composto de tetrahidrooxepinopiridina da presente invenção possui atividade de map sobre um receptor nach a7 e pode ser esperado como agente para prevenir ou tratar a demência, alterações cognitivas, esquizofrenia, mal de alzheimer, acaes, sintomas negativos da esquizofrenia, doenças inflamatórias ou dor.
BR112018003171-2A 2015-08-19 2016-08-18 Compostos de tetrahidrooxepinopiridina, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos BR112018003171B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-162320 2015-08-19
JP2015162320 2015-08-19
PCT/JP2016/074145 WO2017030171A1 (ja) 2015-08-19 2016-08-18 テトラヒドロオキセピノピリジン化合物

Publications (2)

Publication Number Publication Date
BR112018003171A2 true BR112018003171A2 (pt) 2018-09-25
BR112018003171B1 BR112018003171B1 (pt) 2023-09-19

Family

ID=

Also Published As

Publication number Publication date
MX2018002118A (es) 2018-06-18
US9670219B2 (en) 2017-06-06
WO2017030171A1 (ja) 2017-02-23
KR20180037983A (ko) 2018-04-13
ZA201801098B (en) 2019-04-24
CO2018002472A2 (es) 2018-05-31
AR105738A1 (es) 2017-11-01
JPWO2017030171A1 (ja) 2018-06-07
KR102614279B1 (ko) 2023-12-18
EA034794B1 (ru) 2020-03-23
HK1251574A1 (zh) 2019-02-01
IL257450A (en) 2018-04-30
ES2812246T3 (es) 2021-03-16
US20170050973A1 (en) 2017-02-23
CA2995554A1 (en) 2017-02-23
EP3345909A1 (en) 2018-07-11
TW201722962A (zh) 2017-07-01
PT3345909T (pt) 2020-07-29
PH12018500297A1 (en) 2018-08-13
JP6787320B2 (ja) 2020-11-18
CN107922426B (zh) 2021-03-26
EA201890514A1 (ru) 2018-07-31
CA2995554C (en) 2023-06-27
CN107922426A (zh) 2018-04-17
EP3345909B1 (en) 2020-06-17
AU2016308406A1 (en) 2018-03-08
EP3345909A4 (en) 2019-04-10
PL3345909T3 (pl) 2020-10-19
SG11201801193QA (en) 2018-03-28

Similar Documents

Publication Publication Date Title
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112016024472A8 (pt) composto, medicamento, e, uso de um composto
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
BR112018074185A2 (pt) 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
BR112017022666A2 (pt) preparando resposta à alvocidib por perfilamento mitocondrial
BR112015022462A2 (pt) inibidores de ido
CR20170568A (es) Compuesto heterocíclico
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112015021596A2 (pt) moduladores de gpr120 de ácido oxabiciclo[2.2.2]
TW201613890A (en) Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators
BR112015019412A2 (pt) inibidores de bace1
BR112016006154A2 (pt) derivados de indol e indazol
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015019919A2 (pt) compostos bicíclicos
BR112015021990A2 (pt) moduladores de gpr120 de ácido biciclo [2.2.1]
BR112013003481A8 (pt) composto fundido a anel de piridina
BR112017003334A2 (pt) variantes de desintegrina e usos farmacêuticos destas
BR112014017902A2 (pt) Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose
EA201890120A1 (ru) Многофазные композиции
CL2015003563A1 (es) Marcador para trastornos de la esfingomielinasa ácida y sus usos.
BR112014029597A2 (pt) compostos de cromano
BR112015026512A2 (pt) composto acetamida heterocíclico
TR201908151T4 (tr) İzoindolin türevleri.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/2016, OBSERVADAS AS CONDICOES LEGAIS